La vendita allo scoperto per BioLife Solns dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di BioLife Solns. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

BioLife Solns (NASDAQ:BLFS) Azioni, Report sulle vendite allo scoperto

BioLife Solns

BioLife Solutions Inc is active in the healthcare segment. The company is engaged in developing, manufacturing, and marketing a portfolio of biopreservation tools and services for cells, tissues, and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted biologistics cold chain management application for shippers. The company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs.

BioLife Solutions

BioLife Solutions Inc

In the preceding three months, 4 analysts have released ratings for BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $28.25, a high estimate of $30.00, and a low estimate of $26.00. Surpassing the previous average price target of $23.00, the current average has increased by 22.83%.
<img src="https://www.benzinga.com/files/images/story/2024/1727697680_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of BioLife Solns's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$29.00</td>
<td>-</td>
</tr>
<tr>
<td>Matt Hewitt</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Carl Byrnes</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Steven Mah</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$26.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to BioLife Solns. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of BioLife Solns compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of BioLife Solns's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of BioLife Solns's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BLFS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on BioLife Solns analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About BioLife Solns</h2>
BioLife Solutions Inc is active in the healthcare segment. The company is engaged in developing, manufacturing, and marketing a portfolio of biopreservation tools and services for cells, tissues, and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted biologistics cold chain management application for shippers. The company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs.
<h3>BioLife Solns: Delving into Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, BioLife Solns faced challenges, resulting in a decline of approximately -3.11% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: BioLife Solns's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -73.14%, the company may face hurdles in effective cost management.
Return on Equity (ROE): BioLife Solns's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -6.33%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): BioLife Solns's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -5.34%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.11, BioLife Solns adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

BLFS

Key Takeaways From BioLife Solns Analyst Ratings

HC Wainwright &amp; Co. analyst Raghuram Selvaraju initiates coverage on BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) with a Buy rating and announces Price Target of $29.

News

Price Target

Initiation

HC Wainwright & Co. Initiates Coverage On BioLife Solns with Buy Rating, Announces Price Target of $29

Craig-Hallum analyst Matt Hewitt maintains BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) with a Buy and raises the price target from $23 to $30.

Craig-Hallum Maintains Buy on BioLife Solns, Raises Price Target to $30

Northland Capital Markets analyst Carl Byrnes maintains BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) with a Outperform and raises the price target from $26 to $28.

Northland Capital Markets Maintains Outperform on BioLife Solns, Raises Price Target to $28

Raising full-year 2024 total revenue guidance to $99.0 million to $101.0 million; Cell Processing revenue guidance increased to $70.0 million to $71.0 million

Guidance

BioLife Solns Raises FY24 Sales Guidance From $95.50M-$100M To $99M-$101M Vs. $105.79m

BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.14) by 64.29 percent. This is a 61.54 percent increase over losses of $(0.13) per share from the same period last year. The company reported quarterly sales of $28.328 million which beat the analyst consensus estimate of $23.946 million by 18.30 percent. This is a 3.11 percent decrease over sales of $29.237 million the same period last year.

Earnings

Earnings Beats

BioLife Solns Q2 2024 Adj. EPS $(0.05) Beats $(0.14) Estimate, Sales $28.328M Beat $23.946M Estimate

TD Cowen analyst Steven Mah maintains BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) with a Buy and raises the price target from $20 to $26.

TD Cowen Maintains Buy on BioLife Solns, Raises Price Target to $26

WIIM

BioLife Solutions shares are trading higher after Benchmark ugpraded the stock from Hold to Buy and announced a $25 price target.

Benchmark analyst Robert Wasserman upgrades BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) from Hold to Buy and announces $25 price target.

Upgrades

Benchmark Upgrades BioLife Solns to Buy, Announces $25 Price Target

2024 Revenue Guidance
BioLife Solutions is affirming its 2024 revenue guidance of $95.5 million to $100.0 million. This is based on expectations for BioLife's Cell Processing and Biostorage Services platforms, which now include results from its ThawSTAR product line and do not include revenue from the freezer product line (GCI and CBS).
<ul>
<li>Cell Processing platform: $66.0 million to $68.5 million, an increase of 0% to 4% compared with 2023. Compared with annualizing the second half of 2023 revenue run rate, the growth would be 17% to 22% &nbsp;</li>
<li>Biostorage Services platform: $29.5 million to $31.5 million, an increase of 5% to 12% compared with 2023. This platform now includes the ThawSTAR automated thawing product line. Without ThawSTAR, the growth rate would be 10% to 16%.</li>
</ul>

BioLife Solutions Reiterates Guidance

BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.28) by 21.43 percent. The company reported quarterly sales of $16.20 million which missed the analyst consensus estimate of $26.01 million by 37.71 percent. This is a 57.03 percent decrease over sales of $37.70 million the same period last year.

Earnings Misses

BioLife Solns Q1 2024 GAAP EPS $(0.22) Beats $(0.28) Estimate, Sales $16.20M Miss $26.01M Estimate

The Nasdaq 100 closed lower by around 100 points on Thursday. Investors, meanwhile, focused on some notable insider trades.
When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.
Below is a look at a few recent notable insider sales. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading" id="h-meta-platforms">Meta Platforms</h3>
<ul>
<li>The Trade: Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) Chief Legal Officer Jennifer Newstead <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 585 shares</a> at an average price of $498.59. The insider received around $291,675 from selling those shares.</li>
<li>What's Happening: Meta Platforms announced new features in its Meta AI assistant, including expanded availability and real-time image creation capabilities.</li>
<li>What Meta Platforms Does: Meta is the world&#8217;s largest online social network, with nearly 4 billion family of apps monthly active users.</li>
</ul>
Have a look at our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<h3 class="wp-block-heading" id="h-pure-storage">Pure Storage</h3>
<ul>
<li>The Trade: Pure Storage, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>) Chief Revenue Officer Dan Fitzsimons <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 29,283 shares</a> at an average price of $52.14. The insider received around $1.53 million from selling those shares.</li>
<li>What's Happening: On April 11, Susquehanna analyst Mehdi Hosseini maintained Pure Storage with a Positive and raised the price target from $45 to $65.</li>
<li>What Pure Storage Does: Pure Storage Inc is a U.S.-based company that provides an enterprise data storage platform that transforms business through a dramatic increase in performance and reduction in complexity and costs.</li>
</ul>
<h3 class="wp-block-heading" id="h-shoe-carnival">Shoe Carnival</h3>
<ul>
<li>The Trade: Shoe Carnival, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCVL#NASDAQ">SCVL</a>) Director Andrea R. Guthrie <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 2,467 shares</a> at an average price of $32.46. The insider received around $80,079 from selling those shares.</li>
<li>What's Happening: On March 21, Shoe Carnival reported a fourth-quarter FY23 sales decline of 3.7% year-on-year to $280.17 million, marginally missing the analyst consensus estimate of $280.27 million.</li>
<li>What Shoe Carnival Does: Shoe Carnival Inc is a family footwear retailer that offers a broad assortment of dress, casual and athletic footwear for men, women, and children with an emphasis on national name brands such as Nike, Skechers, Adidas, Puma, HEYDUDE, Converse, Vans, and Crocs.</li>
</ul>
<h3 class="wp-block-heading" id="h-biolife-solutions">BioLife Solutions</h3>
<ul>
<li>The Trade: BioLife Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) Chief Marketing Officer Todd Berard <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 10,000 shares</a> at an average price of $15.67. The insider received around $156,700 from selling those shares.</li>
<li>What's Happening: BioLife Solutions announceD the divestiture of its Stirling Freezer Business.</li>
<li>What BioLife Solutions Does: BioLife Solutions Inc is active in the healthcare segment.</li>
</ul>

Check This Out: <a href="https://www.benzinga.com/news/earnings/24/04/38329059/netflix-procter-gamble-and-3-stocks-to-watch-heading-into-friday">Netflix, Procter &amp; Gamble And 3 Stocks To Watch Heading Into Friday</a>

Short Ideas

Insider Trades

Markets

PSTG

SCVL

Meta Platforms, Pure Storage And 2 Other Stocks Insiders Are Selling

BioLife Solutions Completes Divestiture Of Its Stirling Freezer Business; Says Sale Is Expected To Immediately Eliminate 'Several Million Dollars' Of Quarterly Cash Burn And Removes Product Warranty Liabilities, Which Totaled $7.5M As Of December 31, 2023

Jefferies analyst Matthew Stanton initiates coverage on BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) with a Buy rating and announces Price Target of $22.

Jefferies Initiates Coverage On BioLife Solns with Buy Rating, Announces Price Target of $22

BioLife Solutions shares are trading higher after the company reported better-than-expected Q4 adjusted EPS results.

BioLife Solutions Expects 2024 Revenue $95.5M-$100M Excluding Freezer Business

BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) reported its Q4 earnings results on Thursday, February 29, 2024 at 04:00 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
BioLife Solns beat estimated earnings by 38.0%, reporting an EPS of $-0.21 versus an estimate of $-0.34.
Revenue was down $11.53 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.05 which was followed by a 4.0% drop in the share price the next day.
Here's a look at BioLife Solns's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.38</td>
<td>-0.20</td>
<td>-0.21</td>
<td>-0.17</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.33</td>
<td>-0.24</td>
<td>-0.27</td>
<td>-0.19</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>32.94M</td>
<td>43.86M</td>
<td>42.94M</td>
<td>43.28M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>33.33M</td>
<td>39.51M</td>
<td>37.70M</td>
<td>44.26M</td>
</tr>
</tbody>
</table>

To track all earnings releases for BioLife Solns <a href="https://www.benzinga.com/quote/BLFS/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: BioLife Solns Q4 Earnings

BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) reported quarterly losses of $(0.210) per share which beat the analyst consensus estimate of $(0.340) by 38.24 percent. The company reported quarterly sales of $32.732 million which missed the analyst consensus estimate of $33.399 million by 2.00 percent. This is a 26.04 percent decrease over sales of $44.259 million the same period last year.

BioLife Solns Q4 2023 Adj EPS $(0.210) Beats $(0.340) Estimate, Sales $32.732M Miss $33.399M Estimate

BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) is set to give its latest quarterly earnings report on Thursday, 2024-02-29. Here's what investors need to know before the announcement.
Analysts estimate that BioLife Solns will report an earnings per share (EPS) of $-0.34. 
BioLife Solns bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.05, which was followed by a 3.86% drop in the share price the next day.
Here's a look at BioLife Solns's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.38</td>
<td>-0.20</td>
<td>-0.21</td>
<td>-0.17</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.33</td>
<td>-0.24</td>
<td>-0.27</td>
<td>-0.19</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>-28.999999999999996%</td>
<td>-2.0%</td>
<td>8.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1709139665_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of BioLife Solns were trading at $17.11 as of February 27. Over the last 52-week period, shares are down 26.02%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/BLFS/earnings">To track all earnings releases for BioLife Solns visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For BioLife Solns

BioLife Solutions shares are trading higher. The company issued preliminary Q4 and FY23 revenue guidance.

Steven Mah, an analyst from TD Cowen, maintained the Buy rating on BioLife Solutions (BLFS – Research Report). The associated price target remains ...

Buy Rating Justified by BioLife Solutions' Strong Financial Position and Growth Prospects

Lake Street analyst Thomas Flaten maintained a Buy rating on BioLife Solutions (BLFS – Research Report) today and set a price target of $28.00. The...

BioLife Solutions (BLFS) Gets a Buy from Lake Street

BioLife Solutions, Inc. (BLFS) Q2 2024 Earnings Call Transcript

Maxim Group analyst Jason McCarthy has maintained their bullish stance on BLFS stock, giving a Buy rating yesterday. Jason McCarthy has given his B...

Buy Rating Affirmed for BioLife Solutions Amid Strong Market Position and Positive Financial Outlook

Invesco Small Cap Growth Fund Q2 2024 Review

Small-cap and mid-cap Health Care has room to rally - Roth MKM

BioLife Is Cleaning Ship

Conestoga Capital Advisors Q2 2024 Commentary

BioLife Solutions (BLFS) has received a new Buy rating, initiated by H.C. Wainwright analyst, Yi Chen. Yi Chen has given his Buy rating due to a co...

BioLife Solutions: A 'Buy' Rating for its Strategic Positioning in the Expanding CGT Market

Conestoga Capital Advisors Q3 2024 Quarterly Commentary

AAON

ABBV

ACHC

ADMA

AGIO

AGYS

ALTR

ANAB

ANSS

AXON

BDTX

BWMN

CGNX

COCO

CPRT

CRDO

CSGP

CSWI

CWST

CYRX

CYTK

DGII

DSGX

ERII

EXPO

FICO

FIVN

FOXF

FRSH

FTAI

FTAIM

FTAIN

FTAIO

FTAIP

FTNT

GEHC

GKOS

GLOB

GMED

GTLB

GWRE

HALO

HLMN

IDXX

ILMN

INSP

IRMD

ITGR

ITRI

KNSL

LGND

LMAT

LSCC

LSPD

MAMA

MANH

MLAB

MMSI

MNESP

MSTR

NOVT

NTRA

OFLX

ONON

ONTO

PCOR

PLMR

PODD

POOL

PSCH

PYCR

QTWO

REGN

RGEN

RMBS

ROAD

SITE

SITM

SMCI

SNPS

SPSC

SPXC

SSTI

STVN

SUPN

TCYSF

TECH

THBRF

TKNO

TMDX

TMXXF

TREX

TRNS

TWST

USPH

VCEL

VEEV

VRSK

WING

WLDN

Small Cap

Press Releases

BioLife Solutions to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update on February 29, 2024

BioLife Solutions Reports Fourth Quarter and Full Year 2023 Financial Results

BioLife Solutions to Present at TD Cowen and Key Bank Investor Conferences

BioLife Solutions Announces the Divestiture of its Stirling Freezer Business

BioLife Solutions to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024

BioLife Solutions Reports First Quarter 2024 Financial Results

BioLife Solutions Introduces the CellSeal CryoCase™ at International Society for Cell & Gene Therapies (ISCT) Conference in Vancouver

BioLife Solutions to Report Second Quarter 2024 Financial Results and Business Update on August 8, 2024

BioLife Solutions Reports Second Quarter 2024 Financial Results

BioLife Solutions to Report Third Quarter 2024 Financial Results and Business Update on November 12, 2024

Agilent Technologies

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

BioLife Solns

Vendite allo scoperto

BioLife Solns (NASDAQ:BLFS) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO